Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fanping Wang

Cardiovascular Disease Oxnard, CA Medical Doctor

NPI 1710948112 CMS profile 214148

2241 Wankel Way, Ste C, Oxnard, CA 93030

Open in the dashboard

General payments

$15,514

851 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fanping Wang of Oxnard, CA is reported in the CMS Open Payments database as having received $15,514 across 851 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,618 86
2024 General $2,222 105
2023 General $1,962 102
2022 General $2,381 135
2021 General $3,014 157
2020 General $1,863 111
2019 General $2,455 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fanping Wang
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Fanping Wang were reported at $1,618. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Fanping Wang Cardiovascular Disease median Middle half National median
2019 $2,455 $450 $127–$1,392 $163
2020 $1,863 $242 $77–$751 $114
2021 $3,014 $335 $101–$1,037 $132
2022 $2,381 $395 $121–$1,211 $149
2023 $1,962 $443 $136–$1,283 $160
2024 $2,222 $450 $136–$1,323 $164
2025 $1,618 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,084 142 payments
  2. AstraZeneca Pharmaceuticals LP $1,653 86 payments
  3. Novartis Pharmaceuticals Corporation $1,597 98 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,285 73 payments
  5. Janssen Pharmaceuticals, Inc $1,099 68 payments
  6. Amarin Pharma Inc. $969 53 payments
  7. Pfizer Inc. $885 61 payments
  8. Merck Sharp & Dohme Corporation $856 38 payments
  9. E.R. Squibb & Sons, L.L.C. $818 43 payments
  10. Abbott Laboratories $593 9 payments
  11. Other $3,675 180 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,337 845 payments
  2. Education $177 6 payments
Products named General payments · program years 2019–2025
  1. Repatha $1,847 123 payments
  2. LifeVest $1,285 73 payments
  3. XARELTO $1,099 68 payments
  4. VERQUVO $966 43 payments
  5. ENTRESTO $881 56 payments
  6. Vascepa $847 46 payments
  7. BRILINTA $810 43 payments
  8. ELIQUIS $604 32 payments
  9. LEQVIO $558 33 payments
  10. VYNDAQEL $495 36 payments
  11. Other $7,324 368 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,889

Median for Cardiology: 2,533

Drug cost

$733,255

Median for Cardiology: $485,213

Branded share of claims

24.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 211 $200,005
Xarelto Rivaroxaban Brand 119 $137,058
Entresto Sacubitril/Valsartan Brand 78 $96,223
Brilinta Ticagrelor Brand 51 $44,930
Multaq Dronedarone Hcl Brand 30 $41,762
Repatha Sureclick Evolocumab Brand 42 $37,927
Farxiga Dapagliflozin Propanediol Brand 36 $35,607
Vascepa Icosapent Ethyl Brand 58 $29,420
Jardiance Empagliflozin Brand 29 $26,276
Repatha Pushtronex Evolocumab Brand 24 $19,558

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$1,106,718

Of which drugs: $1,655

Medicare patients

784

Average age 77

Services billed

18,392

462 women, 322 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Ischemic heart disease 45%
Arthritis 45%
Chronic kidney disease 38%
Atrial fibrillation 35%
Heart failure 28%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 62 248 $1,655

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
$318 — —
LEQVIO
$163 — —
Repatha
$149 66 —
WAINUA
$114 — —
Arcalyst
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

851 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record